LPCN
Lipocine Inc. NASDAQ Listed Oct 22, 2013$2.39
Mkt Cap $13.9M
52w Low $1.81
5.5% of range
52w High $12.37
50d MA $2.30
200d MA $4.66
P/E (TTM)
-1.2x
EV/EBITDA
—
P/B
0.9x
Debt/Equity
0.0x
ROE
-66.5%
P/FCF
-1.4x
RSI (14)
60.20
ATR (14)
$0.18
Beta
1.09
50d MA
$2.30
200d MA
$4.66
Avg Volume
100.2K
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
675 Arapeen Drive · Salt Lake City, UT 84108 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | -0.60 | -0.34 | +43.3% | 7.88 | +0.9% | +2.9% | +10.9% | -10.5% | -8.8% | -0.7% | — |
| Nov 6, 2025 | AMC | -0.56 | -0.59 | -5.4% | 2.64 | -0.4% | -3.8% | +13.8% | +0.0% | +1.0% | -3.4% | — |
| Aug 5, 2025 | AMC | -0.41 | -0.41 | +0.0% | 3.08 | -1.0% | -1.9% | -1.3% | -1.7% | +0.7% | +0.7% | — |
| May 8, 2025 | AMC | -0.35 | -0.35 | +0.0% | 3.23 | +0.6% | +1.5% | -11.0% | -1.7% | +10.1% | +18.0% | — |
| Mar 13, 2025 | AMC | -0.40 | 0.33 | +182.5% | 3.30 | +1.8% | +1.5% | +4.5% | -1.4% | +6.7% | -4.9% | — |
| Nov 7, 2024 | AMC | -0.48 | -0.44 | +8.3% | 5.59 | -1.3% | -14.8% | +12.0% | -4.3% | +1.6% | +0.6% | — |
| Aug 8, 2024 | AMC | -0.78 | -0.56 | +28.2% | 4.39 | -3.0% | +0.5% | -9.1% | -5.2% | -0.5% | -3.2% | — |
| May 9, 2024 | AMC | -0.68 | 0.66 | +197.1% | 5.24 | +0.4% | +1.5% | -0.8% | +1.3% | +5.0% | +2.3% | — |
| Mar 7, 2024 | AMC | -0.53 | -0.42 | +20.8% | 3.63 | -0.8% | -0.6% | +0.0% | +9.7% | +21.0% | -2.1% | — |
| Nov 8, 2023 | AMC | -0.57 | -1.27 | -122.8% | 2.49 | -1.2% | -4.8% | +5.5% | +11.2% | -3.4% | +1.7% | — |
| Aug 10, 2023 | AMC | -0.64 | -0.68 | -6.2% | 5.01 | -0.2% | +1.4% | -1.6% | +0.0% | -0.2% | -9.2% | — |
| May 11, 2023 | AMC | -0.42 | -0.68 | -61.9% | 4.85 | -9.7% | -11.1% | -0.5% | -17.7% | +2.5% | +1.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $2.05 | $2.09 | +2.0% | -5.4% | +3.1% | +6.5% | -1.9% | +5.3% |
| Jan 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.92 | $10.39 | +4.7% | -2.3% | +7.8% | +4.4% | -1.8% | -3.1% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.92 | $2.86 | -2.1% | -3.4% | +1.8% | +4.5% | +12.7% | -5.0% |
| Aug 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.96 | $3.00 | +1.4% | +2.7% | -1.0% | +3.3% | -2.9% | +2.6% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.22 | $3.37 | +4.7% | +2.2% | -4.0% | +0.9% | -2.5% | -0.3% |
| Jun 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.37 | $3.20 | -5.0% | -2.1% | +0.0% | -4.2% | -1.3% | -1.9% |
| Jul 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.30 | $5.39 | +25.3% | +18.6% | -3.7% | +1.2% | +0.2% | -0.8% |
| Aug 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.80 | $24.31 | +2.1% | -4.3% | -0.7% | +1.5% | -3.0% | +0.0% |
| Jun 24 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $23.12 | $23.97 | +3.7% | +5.1% | +4.9% | -4.0% | -2.1% | -0.7% |
| May 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.57 | $20.57 | +0.0% | +2.5% | -1.6% | +0.0% | +0.0% | -4.1% |
| Dec 10 | Ladenburg Thalmann | Upgrade | Neutral → Buy | — | $22.44 | $22.95 | +2.3% | +3.0% | -3.7% | +2.3% | +2.2% | +0.7% |
| May 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.49 | $16.64 | +0.9% | -3.6% | -1.1% | -1.2% | +0.1% | -2.8% |
| Mar 29 | Seaport Global | Maintains | Buy → Buy | — | $24.82 | $27.20 | +9.6% | +4.8% | -1.3% | -0.7% | +6.7% | +1.9% |
| Feb 27 | Empire Asset Management | Upgrade | Hold → Buy | — | $22.27 | $28.05 | +26.0% | +16.0% | +25.0% | -17.4% | +8.3% | -4.7% |
| Jan 11 | Canaccord Genuity | Downgrade | Buy → Hold | — | $58.82 | $29.75 | -49.4% | -46.0% | -8.6% | -11.1% | -3.3% | -2.7% |
| Oct 7 | H.C. Wainwright | Maintains | Buy → Buy | — | $70.89 | $88.40 | +24.7% | +29.7% | +2.4% | -2.2% | -15.1% | -9.8% |
| Aug 12 | Empire Asset Management | Maintains | Buy → Buy | — | $295.29 | $289.85 | -1.8% | -6.8% | -1.4% | +3.4% | -2.2% | -7.2% |
| Jul 22 | Roth Capital | Maintains | Buy → Buy | — | $200.43 | $212.50 | +6.0% | +16.1% | -1.1% | -4.5% | -3.2% | +4.5% |
| Jul 16 | Evercore ISI | Maintains | Buy → Buy | — | $161.50 | $163.88 | +1.5% | +12.8% | +2.8% | +5.7% | +1.2% | +16.1% |
| Jun 23 | Canaccord Genuity | Maintains | Buy → Buy | — | $137.02 | $139.57 | +1.9% | +4.0% | -4.5% | +2.5% | +2.7% | -3.1% |
No insider trades available.
8-K · 8.01
!! High
Lipocine Inc. -- 8-K 8.01: Material Event / Announcement
Jun 12
8-K · 8.01
!! High
Lipocine Inc. -- 8-K 8.01: Material Event / Announcement
Jun 4
8-K · 8.01
!! High
Lipocine Inc. -- 8-K 8.01: Material Event / Announcement
May 26
8-K · 8.01
!! High
Lipocine Inc. -- 8-K 8.01: Material Event / Announcement
May 19
8-K · 8.01
!! High
Lipocine Inc. -- 8-K 8.01: Material Event / Announcement
Lipocine will present at a virtual healthcare company showcase on May 20, 2026, providing investors an opportunity to hear directly from management about the company's business developments.
May 18
8-K · 2.02
!! High
Lipocine Inc. -- 8-K 2.02: Earnings Results
Lipocine Inc. reported Q1 2026 financial results, with investors now able to assess the biotech company's operational progress and cash burn rate through March 31.
May 7
8-K · 5.02
!!! Very High
Lipocine Inc. -- 8-K 5.02: Executive Change
Lipocine Inc. replaced its Chairman as Spyros Papapetropoulos both assumed and resigned from the role, suggesting potential leadership restructuring or clarification of the company's governance structure.
Apr 21
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
LPCN's Phase 3 trial success for oral brexanolone in postpartum depression could unlock significant revenue potential and validate its oral delivery platform, justifying investor confidence in the commercial pipeline.
Apr 2
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
The corrupted filing appears to contain only image data without disclosed material details, making it impossible to assess whether this 8-K announcement positively or negatively impacts LPCN's stock prospects.
Apr 2
8-K
Unknown — 8-K Filing
Lipocine released 2025 financial results showing its oral delivery platform progress; investors should monitor revenue trends and pipeline advancement to assess whether the company can achieve profitability and validate its drug delivery technology commercially.
Mar 10
8-K
Lipocine Inc. -- 8-K Filing
Lipocine Inc. filed a prospectus supplement on February 26, 2026, indicating the company is proceeding with a registered securities offering under its existing S-3 registration statement.
Mar 4
8-K · 8.01
!! High
Lipocine Inc. -- 8-K 8.01: Material Event / Announcement
Lipocine Inc. updated its investor presentation materials, suggesting potential strategic communications changes but providing no substantive business or financial updates requiring immediate investor reassessment.
Feb 18
8-K · 8.01
!! High
Lipocine Inc. -- 8-K 8.01: Material Event / Announcement
Lipocine completed enrollment in its pivotal Phase 3 trial for LPCN 1154 postpartum depression treatment, a key milestone toward potential FDA approval and commercialization.
Feb 18
Valuation
Market Cap
$13.9M
Enterprise Value
-$1.3M
P/E (TTM)
-1.22x
Forward P/E
—
PEG Ratio
0.00x
P/B
0.90x
P/S
6.81x
P/FCF
-1.40x
EV/EBITDA
—
Shares Out
5.7M
Financials (TTM)
Revenue
$2.0M
Net Income
-$11.4M
EBITDA
-$11.4M
Free Cash Flow
-$9.8M
Op Cash Flow
-$9.8M
EPS Basic
$-1.77
EPS Diluted
$-1.96
EPS Forward
$-1.93
Gross Margin
-8.2%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$17.0M
Total Liab.
$2.5M
Total Equity
$14.5M
Cash
$14.9M
LT Debt
$0
Book Value/Sh
$2.66
Debt/Equity
0.00x
Current Ratio
6.68
Quick Ratio
6.68
Returns & Growth
ROE
-66.5%
ROA
-56.6%
ROIC
-71.6%
Rev Growth YoY
-82.3%
EPS Growth YoY
-110725.0%
Price Returns
2W
+2.1%
1M
+8.1%
3M
+23.2%
6M
-70.1%
12M
-23.2%
Technicals
52W High
$12.37
52W Low
$1.81
50d MA
$2.30
200d MA
$4.66
RSI (14)
60.20
ATR (14)
$0.18
Beta
1.09
Avg Volume
100K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$10.50
High
$15.00
Low
$6.00
Median
$10.50
Data updated apr 25, 2026 7:45pm
· Source: financialmodelingprep.com